Why the study?
Congenital ATIII deficiency can cause severe venous thromboembolism in pregnant patients.
Careful management of anticoagulation therapy, including transitioning from edoxaban to ATIII formulation and unfractionated heparin, can enable successful pregnancy outcomes in patients with congenital ATIII deficiency and prior severe VTE.
Answers are grounded in this paper and cite their sources.
Supports individualized anticoagulation in rare thrombophilias; hypothesis-generating and should not yet change practice.
Congenital ATIII deficiency is one of the congenital thrombophilia diseases that can cause severe venous thromboembolism (VTE) in pregnant patients. A 30-year-old female, 4 gravida and 2 para, came to the emergency department with a complaint of oedema and pain in the left lower leg at 11 weeks of gestation. An inferior vena cava thrombus and pulmonary embolism were found. Because VTE was very severe, artificial abortion was performed, and VTE disappeared rapidly. She maintained oral administration of edoxaban (NOAC) and got pregnant naturally fifty-five weeks later after the abortion. Anticoagulation therapy was changed from NOAC to ATIII formulation and unfractionated heparin at 5 weeks of gestation. The course of pregnancy was good, and a healthy female newborn of 2310 g was delivered vaginally at 37 weeks 6 days of gestation. In puerperium, anticoagulation therapy was changed to warfarin. Currently one and one-half years had passed after delivery and no major adverse events or thrombosis has occurred. This case indicates that severe VTE can develop even in multipara pregnancy and that those who take NOAC may be able to continue pregnancy when they get pregnant.
No takes yet. Share an insight, caveat, or question.
Sakai et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: